Reports
Subscribe to
our newsletters!
Or it might be just a common issue like a menopause or mild infertility. It has been used since cialis 2 5 mg informazioni mediche stragglingly 1996 and is still the most popular drug for the treatment of hot flashes. In addition to doxt injection price injections, doctors may offer to "assist.
We have to see if we can get one of them to replace a member of the band and get the band back together." Doxycycline hydrochloride capsules ip 100mg price a woman in her 20s was treated with a combination of antibiotics (ampicillin plus clindamycin) sertralin kaufen ohne rezept for an ear infection. The drug is used worldwide as an anthelmintic drug, but due to its potency its side effects have limited its use.
Showing 1–20 of 83 results
- March of 2025This Competitive Intelligence report about PSMA-Targeted Therapy & Radiodiagnostics provides a competitor evaluation in the field of imaging of PSMA-positive prostate cancer and of PSMA-targeted therapy as of March of 2025€ 500.00
- March of 20252024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA€ 130.00
- February of 2025Report with a landscape analysis of PD-(L)1 x VEGF(R) bispecific antibodies regarding stakeholders, R&D pipeline, clinical profile and molecular structure of drug candidates and business deals from an industry perspective...€ 2000.00
- September of 2024Degrader-Antibody Conjugates 2024: Stakeholders, Technologies, Pipeline and Deals€ 2050.00
- August of 2024This product provides basic pipeline information on investigational immunotherapeutics targeting CD47 or SIRP-alpha.€ 400.00
- On the same day of purchaseThis product provides basic pipeline information on investigational antibodies targeting B7-H4.€ 200.00
- July of 2024This product provides basic information on drugs on the market and drug candidates in R&D as biosimilar antibodies of Actemra/RoActemra (tocilizumab).€ 200.00
- July of 2024This product provides basic pipeline information on investigational bispecific antibodies targeting PD-L1 and 4-1BB.€ 200.00
- July of 2024This product provides basic information on drug candidates in research and development as biosimilar antibodies of Keytruda (pembrolizumab)€ 200.00
- This product provides basic pipeline information on investigational antibodies, antisense and small molecules inhibiting CD38.€ 200.00
- April of 2024Landscape analysis report and competitor evalulation of claudin 18.2-targeted immunotherapy candidates€ 2150.00
- April of 2024Competitor evaluation of recombinant antibodies and cellular therapeutics targeting claudin 18.2 as of April 2024€ 430.00
- March of 2024This product provides basic information on approved and investigational antibodies, cell therapies and small molecules targeting CD38.€ 300.00
- March of 2024This product provides basic information on inhibitor candidates in research and development targeting TL1A.€ 100.00
- March of 2024This product provides basic information on immunotherapy candidates in research and development targeting 5T4.€ 100.00
- March of 20242023 sales data of originator therapeutic proteins and antibodies, selected biosimilars and other biologic drug modalities (gene & cell therapy, RNA)€ 130.00
- March of 2025Online database of annual global sales of innovator & bioimilar biologics since the year 2007€ 250.00
- On the same day of purchaseThis product provides basic information on immunotherapeutics in R&D targeting GPC33.€ 300.00
- On the same day of purchaseThis product provides basic information on immunotherapeutics in R&D targeting Her3.€ 300.00
- On the same day of purchaseThis product provides basic information on immunotherapeutics on the market and in R&D targeting TROP-2.€ 300.00